Korro Bio, Inc. Increase (Decrease) in Accounts Receivable
Korro Bio, Inc. (KRRO) reported Increase (Decrease) in Accounts Receivable of -$969.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- Korro Bio, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $0.00.
- Korro Bio, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$969.00K, a 525.00% decline year-over-year.
- Korro Bio, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $149.00K, a 91.21% decline year-over-year.
- Korro Bio, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$269.00K.
- Korro Bio, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$727.00K, a 142.87% decline from fiscal 2024.
- Korro Bio, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $1.70M.
- Korro Bio, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$969.00K 10-Q · filed 2026-08-06 | -$820.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$969.00K 10-Q · filed 2026-05-07 | -$820.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.09M derived: sum of 3 quarters · filed 2026-05-07 | -$1.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$120.00K derived: sum of 2 quarters · filed 2026-03-12 | -$955.00K derived: sum of 3 quarters · filed 2026-08-06 | -$727.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$269.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.10M derived: sum of 2 quarters · filed 2026-08-06 | -$876.00K 10-Q · filed 2025-11-12 | $820.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$835.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$607.00K 10-Q · filed 2026-08-06 | $1.09M derived: sum of 3 quarters · filed 2026-08-06 | $1.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $228.00K 10-Q · filed 2026-05-07 | $1.92M derived: sum of 2 quarters · filed 2026-05-07 | $1.92M derived: sum of 3 quarters · filed 2026-05-07 | $1.92M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.70M derived: sum of 2 quarters · filed 2026-03-12 | $1.70M derived: sum of 3 quarters · filed 2026-03-12 | $1.70M 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |